CAMBRIDGE, Mass.--(BUSINESS WIRE)--Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, today announced that it started a Phase 2a clinical trial of ARC1779, which is designed to evaluate the safety and efficacy of ARC1779 as an anti-thrombotic in patients suffering from Acute Coronary Syndrome, or ACS, undergoing emergency percutaneous coronary intervention, or PCI.
